These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24607270)

  • 21. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.
    Pedroza C; Tyson JE; Das A; Laptook A; Bell EF; Shankaran S;
    Trials; 2016 Jul; 17(1):335. PubMed ID: 27450203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes.
    Zhou M; Tang Q; Lang L; Xing J; Tatsuoka K
    Stat Med; 2018 Jun; 37(14):2187-2207. PubMed ID: 29664214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
    Rufibach K; Heinzmann D; Monnet A
    Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.
    Dignam JJ; Bryant J; Wieand HS; Fisher B; Wolmark N
    Control Clin Trials; 1998 Dec; 19(6):575-88. PubMed ID: 9875837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of Predictive Analyses for Interim Decisions in Clinical Trials.
    Avalos-Pacheco A; Ventz S; Arfè A; Alexander BM; Rahman R; Wen PY; Trippa L
    JCO Precis Oncol; 2023 Feb; 7():e2200606. PubMed ID: 36848613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring a randomized clinical trial for futility: the north-Norwegian lidocaine intervention trial.
    Berntsen RF; Rasmussen K; Bjørnstad JF
    Stat Med; 1991 Mar; 10(3):405-12. PubMed ID: 2028124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
    Alikhan MA; Phooskooru V; Kohli M
    J Natl Cancer Inst; 2004 Dec; 96(23):1794; author reply 1794. PubMed ID: 15572762
    [No Abstract]   [Full Text] [Related]  

  • 38. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpreting a Bayesian phase II futility clinical trial.
    Beall J; Cassarly C; Martin R
    Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.